These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

105 related articles for article (PubMed ID: 37542125)

  • 1. The high, and redundant, cost of failure in cancer drug development.
    Mullard A
    Nat Rev Drug Discov; 2023 Sep; 22(9):688. PubMed ID: 37542125
    [No Abstract]   [Full Text] [Related]  

  • 2. The UK Cancer Drugs Fund Experiment and the US Cancer Drug Cost Problem: Bearing the Cost of Cancer Drugs Until It Is Unbearable.
    Prasad V; Mailankody S
    Mayo Clin Proc; 2016 Jun; 91(6):707-12. PubMed ID: 27261866
    [No Abstract]   [Full Text] [Related]  

  • 3. [Cost-effectiveness of cancer drug treatments].
    Akazawa M
    Nihon Rinsho; 2015 Feb; 73 Suppl 2():706-12. PubMed ID: 25831852
    [No Abstract]   [Full Text] [Related]  

  • 4. Rationale and clinical use of multitargeting anticancer agents.
    Melisi D; Piro G; Tamburrino A; Carbone C; Tortora G
    Curr Opin Pharmacol; 2013 Aug; 13(4):536-42. PubMed ID: 23856428
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Targeted Cancer Therapies World Congress 2010--part 2. 21-23 September 2010, Zurich, Switzerland.
    Youssoufian H
    IDrugs; 2010 Dec; 13(12):833-5. PubMed ID: 21154137
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Resistance, the cause of failure in antineoplastic chemotherapies].
    Israel L
    Pathol Biol (Paris); 1989 Feb; 37(2):125-7. PubMed ID: 2652060
    [No Abstract]   [Full Text] [Related]  

  • 7. Network-based approaches for drug response prediction and targeted therapy development in cancer.
    Dorel M; Barillot E; Zinovyev A; Kuperstein I
    Biochem Biophys Res Commun; 2015 Aug; 464(2):386-91. PubMed ID: 26086105
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Criteria for deciding cost-effectiveness for expensive new anti-cancer agents.
    Sarin R
    J Cancer Res Ther; 2008; 4(1):1-2. PubMed ID: 18417893
    [No Abstract]   [Full Text] [Related]  

  • 9. Controlling the cost of innovative cancer therapeutics.
    Malik NN
    Nat Rev Clin Oncol; 2009 Sep; 6(9):550-2. PubMed ID: 19707244
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pharmacy team involvement in navigating the revenue cycle for high-cost medications in patients with cancer.
    Shank BR; Nguyen PAA; Pherson EC
    Am J Manag Care; 2017 Oct; 23(12 Spec No.):SP470-SP473. PubMed ID: 29087665
    [No Abstract]   [Full Text] [Related]  

  • 11. Discovery of small molecules that target autophagy for cancer treatment.
    Wu L; Yan B
    Curr Med Chem; 2011; 18(12):1866-73. PubMed ID: 21466466
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Therapeutic failure of antineoplastic agents. Extracellular and cellular causes].
    Hofsli E
    Tidsskr Nor Laegeforen; 1991 Jan; 111(1):37-40. PubMed ID: 2000585
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Optimum cancer care--an unaffordable goal?
    Ludwig H
    Lancet Oncol; 2004 Sep; 5(9):529-30. PubMed ID: 15337480
    [No Abstract]   [Full Text] [Related]  

  • 14. Patient access schemes for high-cost cancer medicines.
    Williamson S
    Lancet Oncol; 2010 Feb; 11(2):111-2. PubMed ID: 20152762
    [No Abstract]   [Full Text] [Related]  

  • 15. How should we assess the clinical and cost effectiveness of histology independent cancer drugs?
    Cooper S; Bouvy JC; Baker L; Maignen F; Jonsson P; Clark P; Palmer S; Boysen M; Crabb N
    BMJ; 2020 Jan; 368():l6435. PubMed ID: 31896539
    [No Abstract]   [Full Text] [Related]  

  • 16. Grouping of molecularly targeted anti-cancer agents based on cost-effectiveness analysis.
    Tirelli U; Berretta M; Bearz A; Carbone A
    Eur Rev Med Pharmacol Sci; 2011 Nov; 15(11):1355-6. PubMed ID: 22195374
    [No Abstract]   [Full Text] [Related]  

  • 17. Current Cancer Drug Development Strategies.
    Shao J; Gao Y
    Curr Cancer Drug Targets; 2019; 19(4):243-244. PubMed ID: 30968768
    [No Abstract]   [Full Text] [Related]  

  • 18. Why clinical oncologists should talk about the price of cancer drugs.
    Berlinger N
    Virtual Mentor; 2013 Aug; 15(8):677-80. PubMed ID: 23937783
    [No Abstract]   [Full Text] [Related]  

  • 19. Cancer chemotherapy.
    Med Lett Drugs Ther; 1983 Jan; 25(626):1-8. PubMed ID: 6848903
    [No Abstract]   [Full Text] [Related]  

  • 20. The costs of cancer drugs.
    Begg CB
    Clin Trials; 2020 Apr; 17(2):118. PubMed ID: 32070133
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.